Why Capricor Therapeutics, Inc.’s (CAPR) Stock Is Up 8.26%
As of Wednesday, November 18, Capricor Therapeutics, Inc.’s CAPR share price has surged by 8.26%, which has investors questioning if this is right time to sell.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Michael Rose
Michael Rose
Tudor Pop
Michael Rose
| Share Statistics | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $489.0 | $208.2 | 38% |
|
| Shares Out (Mil) | 58.1 | 55.4 | 51% |
|
| Institutional Ownership | 98.5% | 92.9% | 79% |
|
| Float (Mil) | 49.6 | 40.7 | 46% |
|
| Beta | 0.77 | 1.00 | 45% |
|
| Avg Daily Volume (000s) | 5,212 | 570 | 91% |
|
| Price Change (52-week) |
45.8% | 40.7% | 85% |
|
| Growth | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (50.3%) | (10.3%) | 7% |
|
| EPS (5yr) | (20.8%) | 15.5% | 13 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 26.3% | (15.7%) | 84% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 9 | |
| Current EPS | ($0.453) | ($2.453) | ($1.431) | |
| Month Ago EPS | ($0.083) | ($1.452) | ($1.451) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 1 | 1 | |
| Three Months Ago EPS | ($0.081) | ($2.209) | ($1.527) | |
| Year/Year Chg | (38.3%) | 8.5% | (69.2%) | |
| Financials | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($148) | ($44) | 8% |
|
| EPS (TTM) | ($2.654) | ($1.400) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($120) | ($34) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $26 | $-0 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $91 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $547 | $138 | 36% |
|
| Valuation | CAPR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.33 | 1.96 | 62% |
|
| P/E | na | 17.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | CAPR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (64.6%) | (47.4%) | 9% |
|
| ROE | (100.5%) | (51.6%) | 9% |
|
| Liabilities to Assets | 36.5% | 29.7% | 27% |
|
| F-Score | 3 | 3 | 18% |
|
Passing Stock Screens
As of 11/17/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 2.1% |
| +/- S&P 500: | -5.3 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors